SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-029447
Filing Date
2023-06-22
Accepted
2023-06-22 17:02:43
Documents
12
Period of Report
2023-06-22
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K acrv-20230622.htm   iXBRL 8-K 104493
  Complete submission text file 0000950170-23-029447.txt   233313

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acrv-20230622_pre.xml EX-101.PRE 11550
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acrv-20230622_lab.xml EX-101.LAB 18693
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acrv-20230622.xsd EX-101.SCH 2459
6 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20230622_htm.xml XML 4878
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 231034067
SIC: 2834 Pharmaceutical Preparations